This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 08/28/2026
Furuishi et al (2014)1 assessed the stability of VELETRI for infusion (referred to by the authors as Epoprostenol “ACT”) at concentrations ranging from 200 to 30,000 ng/mL. It is stated that the rationale for assessing the stability of VELETRI for infusion at epoprostenol concentrations of <3000 ng/mL (specifically, at 200, 500, and 1000 ng/mL) was that neonatal and infant patients might be administered low doses of VELETRI for the treatment of pulmonary arterial hypertension (PAH), requiring such concentrations in a hospital setting. Stability of VELETRI for infusion solutions was quantified as the percentage of residual epoprostenol at a given time point relative to time zero (hereby referred to as “residual potency”), as assessed by high-performance liquid chromatography. The residual potency of the 200, 500, and 1000 ng/mL solutions was assessed after 4, 8, and 24 hours when stored in the refrigerator (5°C) or at room temperature under diffuse light. When stored at 5°C in the refrigerator, all 3 solutions had ≥90% residual potency up to 24 hours. When stored at room temperature under diffused light, the 500 and 1000 ng/mL solutions had ≥90% residual potency up to 24 hours while the solution at 200 ng/mL epoprostenol had ≥90% residual potency up to 4 hours and <90% residual potency after 8 hours. The starting pH of each solution (9.4, 10.0, and 10.4 for the 200, 500, and 1000 ng/mL solution, respectively) remained similar over the time course of the experiment.1
Of note, a conclusion from both the study described above1 and an earlier study2 that assessed the stability of VELETRI for infusion at epoprostenol concentrations of 3000, 15,000 and 60,000 ng/mL is that the stability of VELETRI decreases with increased dilution of VELETRI for infusion.1,2 In addition, pH decreases with increased dilution of VELETRI for infusion solution.1,2
A literature search of MEDLINE®
| 1 | Furuishi T, Katoh H, Maekawa Y, et al. Stability of Epoprostenol “ACT” in saline solution. J New Rem Clin. 2014;63(6):887-893. |
| 2 |
Would you like to clear and leave your conversation? Message history will be lost.